The National Institute on Aging-Alzheimer’s Association (NIA-AA) adopted atrophy observed on structural MRI as neurodegenerative marker of Alzheimer’s disease (AD) in addition to increased CSF tau, hypometabolism on [18F]-fluorodeoxyglucose-PET, or positive tau PET[3–5]. The gene discussed is MAPT; the disease is Alzheimer disease.